Catalyst Pharmaceuticals Inc (CPRX)
17.59
+0.22
(+1.27%)
USD |
NASDAQ |
Jul 26, 16:00
17.41
-0.18
(-1.02%)
After-Hours: 20:00
Catalyst Pharmaceuticals Price to Book Value: 3.701 for July 26, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| July 25, 2024 | 3.654 |
| July 24, 2024 | 3.684 |
| July 23, 2024 | 3.694 |
| July 22, 2024 | 3.577 |
| July 19, 2024 | 3.564 |
| July 18, 2024 | 3.518 |
| July 17, 2024 | 3.556 |
| July 16, 2024 | 3.574 |
| July 15, 2024 | 3.524 |
| July 12, 2024 | 3.488 |
| July 11, 2024 | 3.432 |
| July 10, 2024 | 3.253 |
| July 09, 2024 | 3.284 |
| July 08, 2024 | 3.250 |
| July 05, 2024 | 3.196 |
| July 03, 2024 | 3.221 |
| July 02, 2024 | 3.324 |
| July 01, 2024 | 3.318 |
| June 28, 2024 | 3.259 |
| June 27, 2024 | 3.164 |
| June 26, 2024 | 3.173 |
| June 25, 2024 | 3.187 |
| June 24, 2024 | 3.238 |
| June 21, 2024 | 3.28 |
| June 20, 2024 | 3.194 |
| Date | Value |
|---|---|
| June 18, 2024 | 3.150 |
| June 17, 2024 | 3.156 |
| June 14, 2024 | 3.168 |
| June 13, 2024 | 3.225 |
| June 12, 2024 | 3.250 |
| June 11, 2024 | 3.274 |
| June 10, 2024 | 3.288 |
| June 07, 2024 | 3.286 |
| June 06, 2024 | 3.316 |
| June 05, 2024 | 3.432 |
| June 04, 2024 | 3.375 |
| June 03, 2024 | 3.404 |
| May 31, 2024 | 3.402 |
| May 30, 2024 | 3.389 |
| May 29, 2024 | 3.341 |
| May 28, 2024 | 3.486 |
| May 24, 2024 | 3.339 |
| May 23, 2024 | 3.349 |
| May 22, 2024 | 3.396 |
| May 21, 2024 | 3.478 |
| May 20, 2024 | 3.560 |
| May 17, 2024 | 3.469 |
| May 16, 2024 | 3.450 |
| May 15, 2024 | 3.505 |
| May 14, 2024 | 3.469 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.965
Minimum
Sep 30 2020
12.09
Maximum
Sep 11 2019
4.253
Average
3.878
Median
Price to Book Value Benchmarks
| Vertex Pharmaceuticals Inc | 6.890 |
| Sarepta Therapeutics Inc | 14.19 |
| PTC Therapeutics Inc | -- |
| Regenxbio Inc | 1.810 |
| Edgewise Therapeutics Inc | 3.312 |
Price to Book Value Related Metrics
| PE Ratio | 32.57 |
| PS Ratio | 4.890 |
| Price to Free Cash Flow | 24.65 |
| Price | 17.59 |
| Earnings Yield | 3.07% |
| Market Cap | 2.078B |
| Operating PE Ratio | 25.68 |
| Normalized PE Ratio | 32.57 |